These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2060531)

  • 21. Primaquine plus clindamycin as a promising salvage therapy for Pneumocystis jirovecii pneumonia: A retrospective analysis in Japanese patients.
    Koga M; Suganuma A; Kikuchi T; Yoshimura Y; Shoji K; Kobayashi I; Takezaki S; Kato Y; Kimura M; Maruyama H;
    J Infect Chemother; 2021 Jun; 27(6):924-928. PubMed ID: 33722465
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clindamycin/primaquine for Pneumocystis carinii pneumonia.
    Ruf B; Pohle HD
    Lancet; 1989 Sep; 2(8663):626-7. PubMed ID: 2570324
    [No Abstract]   [Full Text] [Related]  

  • 23. Anti-Pneumocystis carinii and antiplasmodial activities of primaquine-derived imidazolidin-4-ones.
    Vale N; Collins MS; Gut J; Ferraz R; Rosenthal PJ; Cushion MT; Moreira R; Gomes P
    Bioorg Med Chem Lett; 2008 Jan; 18(2):485-8. PubMed ID: 18077165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Models for evaluating compounds for activity against Pneumocystis carinii.
    Bartlett MS
    Eur J Clin Microbiol Infect Dis; 1991 Mar; 10(3):199-201. PubMed ID: 2060530
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of 8-aminoquinolines on the ultrastructural morphology of Pneumocystis carinii.
    Goheen MP; Bartlett MS; Shaw MM; Queener SF; Smith JW
    Int J Exp Pathol; 1993 Aug; 74(4):379-87. PubMed ID: 8398811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 8-aminoquinolines effective against Pneumocystis carinii in vitro and in vivo.
    Queener SF; Bartlett MS; Nasr M; Smith JW
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2166-72. PubMed ID: 8257140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Toxicity of clindamycin and primaquine treatment of AIDS-related Pneumocystis carinii pneumonia.
    Smith N; Blanshard C; Smith D; Gazzard B
    AIDS; 1993 May; 7(5):749-50. PubMed ID: 8318188
    [No Abstract]   [Full Text] [Related]  

  • 28. Treatment and prevention of Pneumocystis carinii pneumonia and further elucidation of the P. carinii life cycle with 1,3-beta-glucan synthesis inhibitor L-671,329.
    Schmatz DM; Powles M; McFadden DC; Pittarelli LA; Liberator PA; Anderson JW
    J Protozool; 1991; 38(6):151S-153S. PubMed ID: 1818147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A meta-analysis of salvage therapy for Pneumocystis carinii pneumonia.
    Smego RA; Nagar S; Maloba B; Popara M
    Arch Intern Med; 2001 Jun; 161(12):1529-33. PubMed ID: 11427101
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activity of terbinafine against Pneumocystis carinii in vitro and its efficacy in the treatment of experimental pneumonia.
    Contini C; Manganaro M; Romani R; Tzantzoglou S; Poggesi I; Vullo V; Delia S; De Simone C
    J Antimicrob Chemother; 1994 Nov; 34(5):727-35. PubMed ID: 7706168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Case Report: Clindamycin with Primaquine Therapy for Severe Pneumocystis Pneumonia].
    Yoshimura Y; Sakamoto Y; Amano Y; Tachikawa N
    Kansenshogaku Zasshi; 2015 Sep; 89(5):601-5. PubMed ID: 26630794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dilemmas in the prophylaxis of Pneumocystis carinii pneumonia.
    Glatt AE
    South Med J; 1994 Apr; 87(4):429-30. PubMed ID: 8153765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inoculated mouse model of Pneumocystis carinii infection.
    Bartlett MS; Queener SF; Durkin MM; Shaw MA; Smith JW
    Diagn Microbiol Infect Dis; 1992 Feb; 15(2):129-34. PubMed ID: 1572137
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prophylaxis and therapy for Pneumocystis pneumonia--where are we?
    Masur H
    Infect Agents Dis; 1992 Oct; 1(5):270-8. PubMed ID: 1344666
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Standardization of an in vitro drug screening assay by use of cryopreserved and characterized Pneumocystis carinii populations.
    Collins MS; Cushion MT
    J Eukaryot Microbiol; 2001; Suppl():178S-179S. PubMed ID: 11906052
    [No Abstract]   [Full Text] [Related]  

  • 36. Current issues in the treatment and prophylaxis of Pneumocystis carinii pneumonia in HIV infection.
    Morris-Jones SD; Easterbrook PJ
    J Antimicrob Chemother; 1997 Sep; 40(3):315-8. PubMed ID: 9338481
    [No Abstract]   [Full Text] [Related]  

  • 37. In-vitro activity of rifabutin and albendazole singly and in combination with other clinically used antimicrobial agents against Pneumocystis carinii.
    Cirioni O; Giacometti A; Barchiesi F; Fortuna M; Scalise G
    J Antimicrob Chemother; 1999 Nov; 44(5):653-9. PubMed ID: 10552982
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clindamycin-primaquine versus pentamidine for the second-line treatment of pneumocystis pneumonia.
    Kim T; Kim SH; Park KH; Cho OH; Sung H; Kim MN; Choi SH; Jeong JY; Woo JH; Kim YS; Lee SO
    J Infect Chemother; 2009 Oct; 15(5):343-6. PubMed ID: 19856077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methaemoglobinaemia causing progressive dyspnoea and cyanosis during treatment of Pneumocystis jirovecii pneumonia.
    Hamill M; Harte D; Miller RF
    Int J STD AIDS; 2007 Aug; 18(8):577-8. PubMed ID: 17686226
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Growth and metabolism of Pneumocystis carinii in axenic culture.
    Cushion MT; Ebbets D
    J Clin Microbiol; 1990 Jun; 28(6):1385-94. PubMed ID: 2380365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.